Alliance Pharma to acquire LGC's Drug Development Solutions business, with KKR as joint shareholder - Bioanalysis Zone
Alliance Pharma Acquires Drug Development Solutions - PHARMAnetwork news
Ampersand-backed Alliance Pharma to acquire LGC's Drug Development Solutions Business (“DDS”) and welcomes KKR as joint shareholder | Ampersand Capital
LGC has sold DDS to Alliance Pharma, a portfolio company of Ampersand and KKR - Lincoln International LLC
Présentation Activa Capital
In the News
About us | Alliance Pharma
Alliance Pharma Expands Bioanalytical Services | Contract Pharma
RETOURS DES ANCIENS
Alliance Pharma Appoints Patrick Bennett as Chief Executive Officer | Ampersand Capital
Alliance Pharma's Acquisition of LGC's Development Solutions Business – Global Legal Chronicle
Ampersand Invests in Alliance Pharma, Leading Bioanalytical CRO
Alliance Pharma has acquired Drug Development Solutions and attracted KKR as a backer
News - Alliance Pharma | Ryan Klein
Alliance Pharma Acquires LGC's Drug Development Solutions Business | citybiz
Branden Berns on LinkedIn: It's official. The new year has been an excellent occasion to reflect on… | 114 comments
PHARMAnetwork - pharmaceutical CDMO business and contract pharma news - PHARMAnetwork magazine
Jennifer Berlin - Administrative Assistant - Fisher cunnane & Associates | LinkedIn
Ampersand Capital Partners on LinkedIn: EPC Autumn 2022
Ampersand Capital Partners på LinkedIn: U.S. Alliance Pharma Expands Early Phase Bioanalytical Services Into…
LGC has sold DDS to Alliance Pharma, a portfolio company of Ampersand and KKR - Lincoln International LLC
Press release under embargo until Tuesday 17 May 12.00 BST Ampersand-backed Alliance Pharma to acquire LGC's Drug Development
Alliance Pharma Appoints Patrick Bennett as Chief Executive Officer
News - Alliance Pharma | Ryan Klein
